Cost-effectiveness Analysis of Intralesional and Perilesional Recombinant Human Epidermal Growth Factor Vs Hydrocolloid Therapy in Venous Ulcer Treatment in the Colombian Context

Overview

Journal J Vasc Surg Venous Lymphat Disord

Specialties Cardiology & Vascular Diseases
General Surgery

Date 2023 Dec 25

PMID 38145819

Authors

Maria Teresa Cacua Sanchez

Ana Maria Botero

Ornella Moreno-Mattar

Affiliations

Soon will be listed here.

Abstract

Objective: To perform a comparative analysis of health care expenses and outcomes in response to the question: What is the cost-effectiveness of intralesional and perilesional recombinant human epidermal growth factor (rhEGF) compared with hydrocolloid therapy in patients diagnosed with chronic venous insufficiency without infection in Colombia?

Methods: A Markov model was used to determine cost effectiveness over a 5-year period, considering the perspective of the health system in Colombia. The study included patients aged >18 years diagnosed with chronic venous insufficiency and used clinical studies to calculate the probabilities of epithelialization, infection, recurrence, and mortality.

Results: RhEGF is more expensive per unit than hydrocolloids, but it is proven to be effective at healing ulcers in 8 to 12 weeks, even in complex cases. Hydrocolloids, in contrast, typically require 29.5 weeks on average, and ≤46 weeks for complex cases. Despite the cost, rhEGF is more cost effective because it achieves results comparable with hydrocolloid therapy at a lower cost per additional quality-adjusted life-year.

Conclusions: Based on cost-effectiveness analysis, rhEGF is a superior alternative to hydrocolloids for treating venous ulcers in Colombia. Not only is it more affordable, but it also enhances patients' quality of life and streamlines the health care system's resource use.

References

Augustin M, Herberger K, Kroeger K, Muenter K, Goepel L, Rychlik R . Cost-effectiveness of treating vascular leg ulcers with UrgoStart(®) and UrgoCell(®) Contact. Int Wound J. 2014; 13(1):82-7. PMC: 7949993. DOI: 10.1111/iwj.12238. View

Gonzalez-Consuegra R, Verdu J . Quality of life in people with venous leg ulcers: an integrative review. J Adv Nurs. 2011; 67(5):926-44. DOI: 10.1111/j.1365-2648.2010.05568.x. View

Cacua Sanchez M, Buenahora G . Socio-Demographic Characteristics and Associated Factors of Morbidity in Patients with Venous Ulcers Treated in Two Institutions of Contributive and Subsidized Regime in Colombia: Retrospective, Multicenter, Observational Study. Vasc Health Risk Manag. 2022; 18:89-104. PMC: 8901223. DOI: 10.2147/VHRM.S345542. View

Tafernaberry G, Otero G, Agorio C, Dapueto J . [Evaluation of the Charing Cross Venous Ulcer Questionnaire in patients with chronic venous ulcers in Uruguay]. Rev Med Chil. 2016; 144(1):55-65. DOI: 10.4067/S0034-98872016000100008. View

Carter M, Waycaster C, Schaum K, Gilligan A . Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers. Value Health. 2014; 17(8):801-13. DOI: 10.1016/j.jval.2014.08.001. View

Scotton M, Miot H, Abbade L . Factors that influence healing of chronic venous leg ulcers: a retrospective cohort. An Bras Dermatol. 2014; 89(3):414-22. PMC: 4056698. DOI: 10.1590/abd1806-4841.20142687. View

Nherera L, Woodmansey E, Trueman P, Gibbons G . Estimating the Clinical Outcomes and Cost Differences Between Standard Care With and Without Cadexomer Iodine in the Management of Chronic Venous Leg Ulcers Using a Markov Model. Ostomy Wound Manage. 2016; 62(6):26-40. View

Fleurence R, Hollenbeak C . Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2006; 25(1):3-6. DOI: 10.2165/00019053-200725010-00002. View

Guest J, Vowden K, Vowden P . The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. J Wound Care. 2017; 26(6):292-303. DOI: 10.12968/jowc.2017.26.6.292. View

10.

Correa Posada M, Contreras Correa L, Garcia Velez J . Factors associated with chronic venous disease: study in 1,136 patients treated for varicose veins of the lower limbs in a specialized clinic. J Vasc Bras. 2022; 21:e20220051. PMC: 9565676. DOI: 10.1590/1677-5449.202200513. View

11.

Margolis D, Bilker W, Santanna J, Baumgarten M . Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol. 2002; 46(3):381-6. DOI: 10.1067/mjd.2002.121739. View

12.

Gohel M, Barwell J, Taylor M, Chant T, Foy C, Earnshaw J . Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ. 2007; 335(7610):83. PMC: 1914523. DOI: 10.1136/bmj.39216.542442.BE. View

13.

Cacua Sanchez M, Giraldo L, Diaz J . Efficacy of Human Recombinant Epidermal Growth Factors vs Conventional Therapy for the Treatment of Chronic Venous Ulcers: A Retrospective Case Series. Wounds. 2021; 33(2):41-49. View

14.

Carter M . Economic evaluations of guideline-based or strategic interventions for the prevention or treatment of chronic wounds. Appl Health Econ Health Policy. 2014; 12(4):373-89. PMC: 4110411. DOI: 10.1007/s40258-014-0094-9. View

15.

Iglesias C, Birks Y, Nelson E, Scanlon E, Cullum N . Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res. 2005; 14(7):1705-18. DOI: 10.1007/s11136-005-2751-9. View

16.

Brennfleck F, Bongards C . Health economic assessment of negative pressure wound therapy use in the management of subcutaneous abdominal wound healing impairment (SAWHI) in the out-of-hospital setting. Int Wound J. 2022; 20(2):458-466. PMC: 9885446. DOI: 10.1111/iwj.13894. View

17.

Cooper D, Bojke C, Ghosh P . Cost-Effectiveness of PHMB & betaine wound bed preparation compared with standard care in venous leg ulcers: A cost-utility analysis in the United Kingdom. J Tissue Viability. 2023; 32(2):262-269. DOI: 10.1016/j.jtv.2023.03.001. View